Cytosorbents Corporation
CTSO
$0.93
$0.02372.62%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 145.34% | 75.72% | -19.92% | 74.61% | 30.19% |
| Total Depreciation and Amortization | -1.45% | -8.69% | -46.08% | -7.31% | -2.32% |
| Total Amortization of Deferred Charges | 1,881.31% | 1,679.44% | -- | -- | 0.00% |
| Total Other Non-Cash Items | -392.05% | -188.50% | 754.40% | -160.23% | 44,541.46% |
| Change in Net Operating Assets | 145.46% | 76.82% | -519.09% | 660.64% | -124.64% |
| Cash from Operations | 68.50% | 28.26% | 63.45% | 52.73% | 30.85% |
| Capital Expenditure | -107.30% | 95.35% | 27.54% | -6.53% | -108.50% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 6.23% | 44.87% | -36.14% | -27.15% | -46.24% |
| Cash from Investing | -10.76% | 62.83% | 8.61% | -15.79% | -184.82% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | 12,742.29% | -98.63% | -- | -- |
| Repurchase of Common Stock | -450.00% | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -100.01% | 1,294.84% | -98.63% | -115.27% | 956.26% |
| Foreign Exchange rate Adjustments | 471.20% | 346.55% | -7.40% | 268.83% | -99.43% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -128.52% | 160.58% | -143.20% | 42.13% | 182.28% |